Biogen Inc. (BIIB)
Leqembi Isn't Enough To Save Biogen Momentum (Rating Downgrade)
Leqembi Isn't Enough To Save Biogen Momentum (Rating Downgrade)
Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails
DNLI sinks after BIIB122 failed a mid-stage Parkinson's study, prompting Denali and Biogen to halt development in idiopathic cases.
Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish
U.S. Food & Drug Administration (FDA) events crystallize the risk/reward thesis for many biotechnology stocks, and Biogen Inc.'s NASDAQ: BIIB latest Alzheimer's update shows why that trade can turn quickly.
Biogen, Denali scrap Parkinson's drug after failure in mid-to-late stage study
Biogen and Denali Therapeutics said on Thursday they will discontinue development of their Parkinson's drug after it failed to meet the main goal in a mid-to-late stage study.
BIIB Advances Alzheimer's Disease Drug Despite Study Missing Main Goal
Biogen advances Alzheimer's drug diranersen to late-stage trials after a phase II study misses its main goal but shows cognitive and biomarker gains.
Biogen: Apellis Acquisition, Alzheimer's Fail Sums Up Mixed Investment Opportunity
Biogen Inc. is upgraded from Sell to Hold, reflecting recent strategic moves and a modest rebound despite persistent structural challenges. BIIB's acquisition of Apellis for ~$5.6bn adds near-term revenue and nephrology expansion, though realizing a robust kidney franchise remains uncertain. Q1 results were mixed: MS revenues are stable, but long-term decline looms, while new product launches are unlikely before 2028/2029.
Biogen Conference: Lupus, Kidney Programs Take Center Stage in Immunology Push
Biogen NASDAQ: BIIB is continuing to position immunology as a larger part of its strategy, with late-stage lupus and kidney disease programs expected to shape the company's next phase of growth, Adam Meyers, head of the company's immunology and new disease areas franchise, said at Bank of America's annual healthcare conference in Las Vegas.
Biogen Inc. (BIIB) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Biogen Inc. (BIIB) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Biogen Inc. (BIIB) Q1 2026 Earnings Call Transcript
Biogen Inc. (BIIB) Q1 2026 Earnings Call Transcript
Biogen Beats Q1 Earnings Estimates but Cuts 2026 EPS View on M&A Costs
Biogen beats Q1 earnings and revenue estimates, fueled by new drug growth, but cuts 2026 EPS outlook to reflect M&A costs.
Biogen Inc. (BIIB) Tops Q1 Earnings and Revenue Estimates
Biogen Inc. (BIIB) came out with quarterly earnings of $3.57 per share, beating the Zacks Consensus Estimate of $2.95 per share. This compares to earnings of $3.02 per share a year ago.
Biogen cuts annual profit forecast on acquisition-related charges
Biogen cut its full-year profit forecast on Wednesday as it booked acquisition-related charges, although its first-quarter earnings beat expectations on better-than-estimated sales of its Alzheimer's and newer rare-disease treatments.
